Curaleaf Holdings (CURLF) Other Non-Current Liabilities (2019 - 2026)
Curaleaf Holdings (CURLF) posted quarterly Other Non-Current Liabilities of $1.2 million for Q4 2025, down 56.4% year-over-year from $2.8 million in Q4 2024, and down 56.4% quarter-over-quarter from $2.8 million in Q4 2024.
Curaleaf Holdings (CURLF) Other Non-Current Liabilities (2019 - 2026) Analysis & Trends
Curaleaf Holdings' Other Non-Current Liabilities history runs 7 years deep, the most recent figure standing at $1.2 million for Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 56.4% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (down 56.4% YoY), while the FY2025 annual figure was $1.2 million, down 56.4% from the prior year.
- Other Non-Current Liabilities for Q4 2025 stood at $1.2 million, down from $2.8 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $6.6 billion in Q1 2022, with the low at $298000.0 in Q3 2023.
- The 5-year median for Other Non-Current Liabilities is $4.7 million (2023), against an average of $457.6 million.
- The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities surged 348055.95% in 2022, then slumped 96.99% in 2023.
- Curaleaf Holdings' Other Non-Current Liabilities stood at $38.0 million in 2021, then retreated by 23.38% to $29.1 million in 2022, then slumped by 83.77% to $4.7 million in 2023, then sank by 39.94% to $2.8 million in 2024, then tumbled by 56.4% to $1.2 million in 2025.
- Business Quant data shows CURLF's Other Non-Current Liabilities at $1.2 million in Q4 2025, $2.8 million in Q4 2024, and $3.7 million in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.98 Bn | 43.02 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.28 Bn | 39.62 Bn | 2.15 Bn |
| 3 | Zoetis | 31.78 Bn | 30.11 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.71 Bn | 22.91 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn |
| 6 | Viatris | 18.72 Bn | 17.83 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.87 Bn | 11.34 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.97 Bn | - |
| 10 | Curaleaf Holdings | 2.48 Bn | 2.38 Bn | 169.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 468.49 Mn |
| Dec 31, 2025 | 1.24 Mn |
| Dec 31, 2024 | 2.84 Mn |
| Sep 30, 2024 | 3.69 Mn |
| Jun 30, 2024 | 3.50 Mn |
| Dec 31, 2023 | 4.72 Mn |
| Sep 30, 2023 | 298,000.00 |
| Jun 30, 2023 | 103.69 Mn |
| Dec 31, 2022 | 29.11 Mn |
| Sep 30, 2022 | 9.89 Mn |
| Jun 30, 2022 | 1.87 Mn |
| Mar 31, 2022 | 6.61 Bn |
| Dec 31, 2021 | 37.99 Mn |
| Sep 30, 2021 | 26.15 Mn |
| Jun 30, 2021 | 29.11 Mn |
| Mar 31, 2021 | 1.90 Mn |
| Dec 31, 2020 | 1.90 Mn |
| Sep 30, 2020 | 41.23 Mn |
| Dec 31, 2019 | 32.62 Mn |